Zhongguo aizheng zazhi (Jul 2022)
Chinese experts consensus on quality control standards for tumor organoids diagnosis and treatment platform (2022 version)
Abstract
Recently, advances in organoid technology have opened new avenues for the development of novel models of human cancer. Patient-derived tumor organoids retain phenotypes such as histopathological, genetic and molecular features of the original tumor. The generation of cancer, more closer to the real pathophysiological status organoids from primary patient material enables a range of therapeutic agents to be tested in the resulting organoid cultures that not only can be an excellent and innovative platform for drug discovery, but also through sensitivity test of the drug candidates can predict patient response to therapy, thereby holding great promise for personalized medicine. However, compared to traditional biobanks, living biobanks from patient-derived organoids requires stricter quality control and higher level of technical standards. With further research of organoids, a variety of solid tumors have been covered. Organoid technology was named technology of the year in life sciences in 2017. There is no quality control standard for the construction, identification and drug-screening applications of patient-derived cancer organoids in China, and there is also a lack of experts consensus for drug sensitivity test to guide precise tumor treatment. Therefore, based on the advances of patient-derived tumor organoids at home and abroad in the precision medicine, the Multidisciplinary Diagnosis and Treatment Professional Committee of China Anti-cancer Association and the Tumor Endocrinology Professional Committee of China Anti-cancer Association have formulated “Chinese experts consensus on quality control standards for tumor organoids diagnosis and treatment platform (2022 version)”, which improves the understanding of Chinese clinicians and medical researchers on organoids’ drug sensitivity test, standardizes the quality of tumor organoids diagnosis and treatment platform, and guide its clinical application in the domestic precision medicine. This consensus will be regularly updated based on the further research on organoids.
Keywords
